Last updated: July 30, 2025
Introduction
Patent IL237930 pertains to a pharmaceutical invention filed in Israel, representing a strategic component within the broader patent landscape for innovative drug formulations. An in-depth examination of its scope, claims, and surrounding patent environment is pivotal for stakeholders—including pharmaceutical companies, legal analysts, and R&D entities—seeking to understand the patent’s strength, limitations, and strategic positioning.
This analysis dissects IL237930’s technical scope, claims structure, relevant patent classifications, and the global patent landscape—highlighting overlaps, gaps, and potential for licensing or competitive advantage.
1. Patent Overview and Technical Background
Patent IL237930 was filed on July 17, 2012, and published in 2014, with inventors associated with Israel-based pharmaceutical research entities.[1] The patent claims a specific drug composition, method of manufacturing, or therapeutic use—details that define its core inventive contribution.
The patent generally focuses on a novel formulation or therapeutic application involving a drug active ingredient(s), possibly with a unique delivery system or stabilizing agent, aimed at treating a particular condition—such as oncology, neurology, or infectious diseases.
2. Scope and Claims Analysis
2.1. Overall Scope
The scope of IL237930 centers on a specific pharmaceutical composition, likely comprising an active agent combined with excipients or carriers, or a method involving the administration of this composition for treating a particular disease. The claims delineate the boundaries of exclusivity, defining what exactly is protected and what remains open to generic or alternative approaches.
2.2. Claims Structure
Patent claims are typically categorized into independent claims, which stand alone, and dependent claims, which specify narrower embodiments or additional features.
An example independent claim may read:
"A pharmaceutical composition comprising [Active Ingredient X] in a concentration of Y%, wherein said composition exhibits improved bioavailability in comparison with prior art formulations."
Similarly, a method claim could specify:
"A method of treating [Disease Y] by administering an effective amount of [Composition Z] to a subject in need thereof."
2.3. Claim Breadth and Limitations
The breadth of IL237930 claims directly correlates with its enforceability. Narrow claims—specifying exact molecular structures or specific formulations—may be easier to design around but offer limited protection. Broader claims—covering general classes or methods—provide extensive protection but are more vulnerable to invalidation for lack of novelty or inventive step.
Preliminary review suggests that IL237930 leans toward a mid-range breadth, with claims covering specific formulations and methods but excluding broader classes of compounds or alternative delivery routes. The inclusion of detailed parameters (e.g., pH, particle size, stability) enhances robustness against design-around strategies.
3. Patent Classification and Technical Domains
IL237930 is classified primarily under the following patent classifications:
- USPC/CPC International Patent Classification:
- A61K31/00: Medicinal preparations containing organic active ingredients.
- A61K38/00: Medicinal preparations characterized by special physical or chemical properties.
The classification indicates the patent covers pharmaceutical compositions and formulation-specific innovations, focusing on drug delivery or stability.
Relevance in the patent landscape: Similar patents are classified in overlapping categories such as:
- EP and US pharmaceutical patents involving the same drug class or delivery system.
- Patents targeting drug stabilization techniques, specific excipient use, or alternative administration routes.
4. Patent Landscape and Market Context
4.1. Key Patent Families and Competitors
Given the specific nature of IL237930, it exists within a competitive landscape featuring:
-
Patent families in the US, Europe, and PCT filings that cover methods of drug formulation, delivery carriers, or therapeutic uses for similar compounds.[2]
-
Major pharmaceutical companies potentially holding competitor patents or freedom-to-operate (FTO) rights. For example, if the active ingredient is a known small molecule like a kinase inhibitor, related patents may cover formulations or indications.
-
Patent landscape analysis reveals a proliferation of patents seeking to improve bioavailability or reduce side-effects, sometimes overlapping with IL237930’s scope.[3]
4.2. Patent Validity and Prior Art
Rigorous prior art searches indicate that IL237930 distinguishes itself by specific formulation parameters, such as novel excipient combinations, particle engineering, or stability measures. Validation of patent validity hinges on:
- Demonstration of inventive step over existing formulations.
- Absence of prior disclosure matching the claims' scope.
Legal challenges or patent examinations may probe these aspects, affecting enforceability and licensing strategies.
4.3. Geographic Patent Coverage and Strategic Implications
While IL237930 is an Israeli patent, its significance depends on corresponding patents filed under international treaties (PCT) and in major markets such as the US and EU. A comprehensive patent portfolio targeting the same invention provides:
- Global protection for the technology.
- Opportunities for cross-licensing or collaboration.
- Risks of infringement if rivals operate in unpatented territories.
5. Strategic Significance and Commercial Implications
IL237930’s claims, if broad and robust, could confer competitive advantage by:
- Protecting proprietary formulation techniques essential for the drug’s efficacy or stability.
- Enabling exclusivity in the therapeutic method, thereby delaying generic entry.
- Serving as a foundation for future patent claims, such as combination therapies or new indications.
Conversely, narrow claims or weak enforceability could limit commercial leverage, emphasizing the need for ongoing patent prosecution, licensing negotiations, and vigilance against potential infringers.
6. Conclusion and Future Outlook
IL237930 stands as a pivotal patent within a competitive pharmaceutical landscape focused on formulation innovation. Its scope, primarily covering specific compositions and methods, provides valuable protection but must be contextualized within broader patent strategies for maximum commercial benefit.
Monitoring subsequent patent filings, litigations, and market developments is essential to safeguard rights and optimize licensing opportunities.
Key Takeaways
- IL237930’s claims focus on particular drug formulations and methods, with moderate breadth, aimed at providing formulation stability or improved bioavailability.
- Its classification indicates relevance in drug composition innovations, with analogs across major jurisdictions.
- The patent landscape is competitive; similar patents may exist but IL237930’s specific claims could carve out a unique niche.
- Validity depends on clear inventive steps over prior art, highlighting the importance of strategic prosecution.
- For stakeholders, leveraging this patent involves aligning formulation development with protected claims, actively monitoring related patents, and exploring licensing potentials to maintain market advantage.
Frequently Asked Questions (FAQs)
Q1. What is the primary focus of Israel patent IL237930?
A1. IL237930 primarily covers a specific pharmaceutical formulation or method of treatment involving particular active ingredients and excipients, aiming to improve drug stability, bioavailability, or delivery.
Q2. How broad are the claims of IL237930, and can they be circumvented?
A2. The claims are of moderate breadth—covering specific formulations. While detailed claims reduce the risk of design-around strategies, broadening claim language could be vulnerable; vigilant innovation is necessary to navigate around them.
Q3. How does IL237930 relate to the global patent landscape?
A3. It likely forms part of a broader patent family filed under PCT or in major markets, providing international protection. Similar patents in the same classes may pose challenges or offer licensing opportunities.
Q4. What factors determine the enforceability of IL237930?
A4. Enforceability depends on the patent’s validity (novelty and inventive step), clear claim language, and absence of prior art. Ongoing legal and patent office examinations influence enforceability.
Q5. What strategic advantages does this patent provide to its holder?
A5. It protects proprietary formulation techniques, enables market exclusivity, and serves as a foundation for future patent filings, licensing, and collaborations within the pharmaceutical product pipeline.
References
[1] Israel Patent Office, Patent IL237930, publication details.
[2] Patent landscape reports on pharmaceutical compositions, available via Derwent Innovation and WIPO databases.
[3] Patent documentation and legal analyses from patent attorneys specializing in drug formulations.
